Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey.

导出 LinkOut

翻译打印收藏纠错

作者： Ayşe Hilal Eroğlu,Küçükdiler ^[1] ; İrfan,Yavaşoğlu ^[1] ; Cem,Selim ^[1] ; Cansu Atmaca,Mutlu ^[2] ; Abdullah,Karakuş ^[3] ; Mahmut Bakır,Koyuncu ^[4] ; Oktay,Bilgir ^[2] ; Orhan,Ayyıldız ^[3] ; Eyüp Naci,Tiftik ^[4] ; Ali Zahit,Bolaman ^[1]

作者单位： Aydin Adnan Menderes University Faculty of Medicine, Department of Hematology, Turkey. ^[1] Izmir Bozyaka Training and Research Hospital, Department of Adult Hematology, Turkey. ^[2] Dicle University Faculty of Medicine, Department of Adult Hematology, Turkey. ^[3] Mersin University Faculty of Medicine, Department of Adult Hematology, Turkey. ^[4]

关键词 Acute myeloid leukemia Gemtuzumab ozogamicin Salvage treatment

DOI 10.1016/j.lrr.2021.100280

PMID 34849337

发布时间 2021-12-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Leukemia research reports

2021年16卷

100280页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey.

Leukemia research reports

相似文献

Leukemia research reports

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey.

Leukemia research reports

相似文献

Leukemia research reports

相关期刊

检索历史清除